NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.
Kurt
K
Samson
D000409:Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy; D000682:Amyloid / Q000737:chemistry; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D001381:Azepines / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008958:Models, Molecular
D000682:Amyloid; D001381:Azepines; D015415:Biomarkers; C484278:N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide; D053829:Amyloid Precursor Protein Secretases; D000409:Alanine